Testing serine with fluorouracil for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a supplement called serine to standard chemotherapy (fluorouracil) is safe and works better for advanced colorectal cancer. It is for people who have not yet started treatment with fluorouracil drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced colorectal cancer that has been confirmed by a biopsy or other test.
- You are eligible to receive treatment with a fluorouracil-based drug as your first therapy.
- You have at least one tumor that can be measured on scans.
- You are able to take care of yourself (ECOG score of 0, 1, or 2).
- Your doctor expects you to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
This trial tests an immunotherapy drug (serplulimab) combined with targeted therapy, chemo, and radiation as a first treatment for people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if this combination can help control the cancer.
This trial tests putting a chemo drug (fluorouracil) directly into the colon through a tube. It's for people with colorectal cancer who are already getting other cancer treatment, to see if adding local chemo helps shrink the main tumor.
This study tests a combination of three drugs—fruquintinib (an anti-angiogenic agent), serplulimab (an immune-boosting antibody), and standard chemotherapy—as a first-line treatment for advanced colorectal cancer with specific genetic mutations. The goal is to see if this combination can help shrink or control tumors better than standard treatment alone.
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.